GREEN VISION BIOTECHNOLOGY CORP. - FORM 8-K - EX-16.1 - LBB & ASSOCIATES - May 12, 2017

Attached files

file filename
EX-99.2 - UNAUDITED PRO FORMA - GREEN VISION BIOTECHNOLOGY CORP.vibx_ex992.htm
EX-99.1 - AUDITED CONSOLIDATED FINANCIAL STATEMENTS - GREEN VISION BIOTECHNOLOGY CORP.vibx_ex991.htm
EX-10.4 - ESCROW AGREEMENT - GREEN VISION BIOTECHNOLOGY CORP.vibx_ex104.htm
EX-10.3 - VOTING RIGHTS PROXY - GREEN VISION BIOTECHNOLOGY CORP.vibx_ex103.htm
EX-10.2 - OPERATING AGREEMENT - GREEN VISION BIOTECHNOLOGY CORP.vibx_ex102.htm
EX-10.1 - CONSULTING SERVICES AGREEMENT - GREEN VISION BIOTECHNOLOGY CORP.vibx_ex101.htm
EX-2.2 - SHARE EXCHANGE AGREEMENT - GREEN VISION BIOTECHNOLOGY CORP.vibx_ex22.htm
EX-2.1 - SHARE EXCHANGE AGREEMENT - GREEN VISION BIOTECHNOLOGY CORP.vibx_ex21.htm
8-K - FORM 8-K - GREEN VISION BIOTECHNOLOGY CORP.vibx_8k.htm

EXHIBIT 16.1

 

 

 

 

May 12, 2017 

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-7561

 

Ladies and Gentlemen:

 

Green Vision Biotechnology Corp., (the “Company”) provided to us a copy of the Company’s response to Item 4.01 of Form 8-K, dated May 12, 2017. We have read the Company’s statements included under Item 4.01 of its Form 8-K and we agree with such statements insofar as they relate to our firm.

 
 

Yours truly,

 

/s/ LBB & ASSOCIATES LTD., LLP

LBB & ASSOCIATES LTD., LLP

 

 

 

 

GREEN VISION BIOTECHNOLOGY CORP. Reports